---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-000578"
form_type: "8-K"
ticker: "LFWD"
cik: "0001607962"
company_name: "Lifeward Ltd."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:44:51.376971+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lifeward enters $525K secured note with Oramed at 24% interest, expandable by $975K

## Summary
- Initial principal $525,000; mutual consent can increase by up to $975,000 for total up to $1.5M.
- Interest at 24% per annum; matures earlier of August 12, 2026 or failure to obtain shareholder approval.
- Note secured by lien on company's cash; proceeds applied ratably with existing $3M secured note.
- Customary covenants limit additional debt, liens, asset sales, and affiliate transactions.
- Events of default include non-payment, covenant breach, insolvency, or material adverse effect.

## SEC filing metadata
- accession: 0001178913-26-000578
- form_type: 8-K
- ticker: LFWD
- cik: 0001607962
- company_name: Lifeward Ltd.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/zk2634413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-000578
- JSON: https://secwatch.observer/filing/0001178913-26-000578.json
- Plain text: https://secwatch.observer/filing/0001178913-26-000578.txt

## Key facts
- Debt Financings
  Lifeward Ltd. incurred loan of initial principal amount of $525,000 with Oramed Pharmaceuticals, Inc. at 24% per annum maturing the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval.
  - Instrument: loan
  - Principal: initial principal amount of $525,000
  - Counterparty: Oramed Pharmaceuticals, Inc.
  - Rate: 24% per annum
  - Maturity: the earlier of (i) August 12, 2026 and (ii) the failure of the Company to obtain shareholder approval
  - Event: incurrence
  source text: On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm
- Material Agreements
  Lifeward Ltd. entered into Subsequent Secured Promissory Note with Oramed Pharmaceuticals, Inc. valued at initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 (effective 2026-02-12).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Oramed Pharmaceuticals, Inc.
  - Value: initial principal amount of $525,000, which amount may be increased by up to an additional $975,000
  - Effective: 2026-02-12
  source text: On February 12, 2026, the Company entered into a Secured Promissory Note (the “Subsequent Secured Promissory Note”) with Oramed Pharmaceuticals, Inc. (“Oramed”) pursuant to which the Company issued to Oramed a secured promissory note in the initial principal amount of $525,000, which amount may be increased by up to an additional $975,000 upon the mutual consent of the parties.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1607962/000117891326000578/0001178913-26-000578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.